The ASCRS clinical practice guidelines for fecal incontinence (FI) states that up to 18% of the general population worldwide suffer from FI.1 However, due to the shame and emotional toll of this condition - many people avoid seeking treatment, and the number of cases is likely higher.2
Solesta is an injectable outpatient procedure for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy (e.g. diet, fiber therapy, antimotility medications, pelvic floor exercises (Kegels), biofeedback).
Efficacy and Safety of Solesta: Overview of the prospective, single-arm, multicenter, clinical study with 36 month follow-up.
Paquette IM, Varma MG, Kaiser AM, Steele SR, Rafferty JF. The American Society of Colon and Rectal Surgeons’ Clinical Practice Guideline for the Treatment of Fecal Incontinence. Dis Colon Rectum. 2015;58:623–636.
Irwin T, Snow AR, Orton TS, Elliot C. Endoscopic, ultrasonographic, and histologic descriptions of dextranomer/hyaluronic acid in a case of fecal incontinence. Case Reports in Pathology. 2018.